Comparative study of the impact of adjuvant trastuzumab and its biosimilars on cardiac function in HER2-positive early breast cancer patients: a single-center study
{{output}}
Introduction: Two trastuzumab biosimilars have been introduced into the local public healthcare system since April 2021 as alternatives for treatment of human epidermal growth factor receptor (HER2) positive breast cancer. While ... ...
